Jeffrey Humphrey
Net worth: - $ as of 31/03/2024
Career history of Jeffrey Humphrey
Former positions of Jeffrey Humphrey
| Companies | Position | Start | End |
|---|---|---|---|
| CYTEIR THERAPEUTICS, INC. | Director/Board Member | 15/12/2021 | 29/11/2023 |
| Independent Dir/Board Member | 15/12/2021 | 29/11/2023 | |
| MAGENTA THERAPEUTICS | Chief Tech/Sci/R&D Officer | 04/10/2021 | 01/08/2022 |
| CONSTELLATION PHARMACEUTICALS, INC. | Chief Tech/Sci/R&D Officer | 22/06/2020 | 15/07/2021 |
| KYOWA KIRIN CO. LTD. | Corporate Officer/Principal | 01/08/2019 | 01/06/2020 |
Kyowa Kirin Pharmaceutical Development Ltd.
 Kyowa Kirin Pharmaceutical Development Ltd. Miscellaneous Commercial ServicesCommercial Services Kyowa Kirin Pharmaceutical Development Ltd. engages in developing pharmaceutical products. The company was founded on December 31, 1996 and is headquartered in London, the United Kingdom. | Chief Tech/Sci/R&D Officer | 01/04/2013 | 01/08/2019 |
| President | 01/04/2013 | 01/08/2019 | |
| Kyowa Hakko Kirin Pharma, Inc. | Corporate Officer/Principal | 01/04/2012 | 01/03/2013 |
Training of Jeffrey Humphrey
| Harvard College | Undergraduate Degree |
| Case Western Reserve University School of Medicine | Doctorate Degree |
Statistics
International
| United States | 7 |
| Japan | 2 |
| United Kingdom | 2 |
Operational
| Chief Tech/Sci/R&D Officer | 3 |
| Corporate Officer/Principal | 2 |
| Doctorate Degree | 1 |
Sectoral
| Health Technology | 5 |
| Consumer Services | 3 |
| Commercial Services | 2 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
| Listed companies | 2 |
|---|---|
| KYOWA KIRIN CO. LTD. | Health Technology |
| CYTEIR THERAPEUTICS, INC. | Health Technology |
| Private companies | 4 |
|---|---|
| Kyowa Hakko Kirin Pharma, Inc. | |
Constellation Pharmaceuticals, Inc.
 Constellation Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Constellation Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of novel therapeutics in the field of epigenetics. The firm utilizes epigenetics platform, which enables to validate targets and generate small molecules against these targets that selectively modulate gene expression in tumor and immune cells to drive anti-tumor activity. Its product include CPI-0610, CPI-1205, and CPI-0209. The company was founded by Danny Reinberg, David Allis, and Yang Shi on January 11, 2008 and is headquartered in Cambridge, MA. | Health Technology |
Magenta Therapeutics, Inc.
 Magenta Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Magenta Therapeutics, Inc. is a biotechnology company, which focuses on improving stem cell transplantation. Its platform includes MGTA-117, MGTA-145, and CD45-ADC. The company was founded by David T. Scadden, Derrick J. Rossi, Alan Tyndall, Luigi Naldini, Robert Negrin, John F. Dipersio, and Jason Gardner on June 17, 2015 and is headquartered in Cambridge, MA. | Health Technology |
Kyowa Kirin Pharmaceutical Development Ltd.
Kyowa Kirin Pharmaceutical Development Ltd. Miscellaneous Commercial ServicesCommercial Services Kyowa Kirin Pharmaceutical Development Ltd. engages in developing pharmaceutical products. The company was founded on December 31, 1996 and is headquartered in London, the United Kingdom. | Commercial Services |
- Stock Market
- Insiders
- Jeffrey Humphrey
- Experience
